A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with CAP including COVID-19 pneumonia.
This study is testing a new medicine, trimodulin, for adults who are in hospital with pneumonia. This includes lung infections not caused by COVID-19 (called Community-Acquired Pneumonia or CAP) and pneumonia caused by the COVID-19 virus. The main goal is to find out if trimodulin can stop people from getting worse or dying, compared to a placebo (a dummy treatment). Researchers will also check how safe trimodulin is and look at other things like how quickly people get better and how long they stay well after treatment. The study is 'double-blind', meaning neither patients nor their doctors will know if they're receiving trimodulin or the placebo until after the study is over.
At a glance
What is this study about?
This study is a big step in understanding how to help people seriously ill with pneumonia. Pneumonia is a common and sometimes very serious lung infection, and this study looks at two types: pneumonia people get from their everyday life (Community-Acquired Pneumonia, or CAP) and pneumonia caused by the COVID-19 virus. When someone is very unwell in hospital with these conditions, doctors are always looking for better ways to help them recover and prevent serious complications.
The new treatment being tested is called trimodulin. It's a special solution given through a drip, and it contains important antibodies (proteins the body uses to fight infection). Researchers want to see if giving these antibodies can boost the body's ability to fight the infection and help patients improve. They are comparing it to a "placebo," which looks exactly like the real treatment but doesn't contain the active medicine – this helps them know if any improvements are genuinely due to trimodulin.
The main aim is to see if trimodulin can reduce the chances of a patient getting worse or even dying. The study also carefully checks for any side effects and measures how quickly people recover. The information gained from this study could help doctors decide if trimodulin should become a standard treatment for people with these types of pneumonia in the future.
Key takeaways
- Tests a new medicine (trimodulin) for hospitalized adults with pneumonia, including COVID-19 related pneumonia.
- Compares trimodulin to a dummy treatment (placebo) to see if it's effective and safe.
- Neither patients nor doctors know who gets the real medicine (double-blind study).
- Main goal: see if trimodulin reduces worsening of illness or death.
- Regular checks on health, symptoms, and potential side effects.
- Participation involves monitoring while in hospital and follow-up for up to 90 days.
Who may be eligible?
This study is looking for adult patients who are currently in hospital with pneumonia. To take part, you need to be at least 18 years old.
The pneumonia you have could be 'Community-Acquired Pneumonia' (CAP), which means you caught it outside of a hospital setting. Alternatively, you might have moderate or severe pneumonia specifically caused by the COVID-19 virus. The doctors involved in the study will check specific details of your condition to make sure you fit the study requirements.
There will also be other health conditions or medications that might mean you can't join the study, so your hospital medical team will carefully review your full medical history to confirm if this study is suitable for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you currently in hospital because of pneumonia?
- Is your pneumonia either 'Community-Acquired' (meaning you caught it from everyday life) or caused by COVID-19?
- Are you able to follow the study procedures, for example, attending follow-up appointments?
- Your doctor will need to check your full medical history for other conditions that might prevent you from joining.
What does participation involve?
If you decide to take part in this study, you would receive the study treatment, either trimodulin or a placebo, through an intravenous drip while you are in the hospital. This treatment would be given for a specific period. Throughout your time in the study, doctors and nurses would regularly check your health, take blood samples, and monitor your symptoms and recovery. They would also keep a close eye on any side effects you might experience.
Even after you leave the hospital, the study team would follow up with you to see how you are doing, usually for a period of up to 90 days. This might involve phone calls or shorter check-up appointments. The total length of your participation, including follow-up, would be made clear to you by the study team.
Potential risks and benefits
Locations (9)
- —UnverifiedBelgium
- —UnverifiedAustria
- —UnverifiedSlovakia
- —UnverifiedGermany
- —UnverifiedLithuania
- —UnverifiedHungary
- —UnverifiedFrance
- —UnverifiedLatvia
- —UnverifiedPortugal
Common questions
What is 'pneumonia'?
Pneumonia is an infection that inflames the air sacs in one or both lungs. The air sacs may fill with fluid or pus, causing cough, fever, chills, and difficulty breathing.
What does 'placebo-controlled' mean?
It means some people will get the new treatment and others will get a 'dummy' treatment (placebo) that looks the same but has no active medicine. This helps researchers see if the new medicine really works.
What does 'double-blind' mean?
It means that neither you nor your doctor will know if you are receiving the new treatment or the placebo. This helps make sure the study results are fair and unbiased.
What is trimodulin?
Trimodulin is a special medicine given through a drip containing important antibodies. These are proteins your body uses to fight off infections.
Will I still get my usual treatment?
Yes, all participants in the study will continue to receive the standard medical care for their pneumonia, in addition to the study treatment.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.